Have any questions? 706-721-6582 or cts@augusta.edu
- Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications
Clinical Trial
Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of the investigational drug, dipraglurant (ADX48621), in subjects with Parkinsons disease (PD) and levodopa-induced dyskinesia (LID).
Eligibility Criteria
- Has been diagnosis Parkinsons Disease PD Patient is 30 to 85 years old
RESEARCH. INNOVATION. DISCOVERY.